Get access

Intravenous immunoglobulin for Wegener's granulomatosis

  • Protocol
  • Intervention

Authors

  • Patricia M Fortin,

    Corresponding author
    1. University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, BC, Canada
    • Patricia M Fortin, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. pfortin@telus.net.

    Search for more papers by this author
  • Aaron Tejani,

    1. Fraser Health Authority, Clinical Research and Drug Information, Burnaby, BC, Canada
    Search for more papers by this author
  • Ken Bassett,

    1. University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, BC, Canada
    Search for more papers by this author
  • Vijaya M Musini

    1. University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, BC, Canada
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to determine from a systematic review of randomized and quasi-randomized controlled trials if intravenous immunoglobulin adjuvant therapy provides a therapeutic advantage over and above treatment with systemic corticosteroids in combination with immunosuppressants for the treatment of Wegener's granulomatosis.

Get access to the full text of this article